[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356264-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356264-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","recent-advances-in-bispecific-antibody-drug-conjugates-for-breast-cancer-therapy","Recent advances in bispecific antibody-drug conjugates for breast cancer therapy","","Bispecific antibody-drug conjugates (BsADCs) provide a strategy to address key shortcomings of conventional antibody-drug conjugates in breast cancer, including tumor heterogeneity and inefficient intracellular uptake. The review synthesizes recent therapeutic advances and evaluates translational potential by examining clinically relevant BsADC candidates, their mechanistic designs, and activity in difficult subtypes. Focus includes dual-target drug delivery, receptor clustering and fast-internalization, targeting compensatory resistance pathways, and improvements from linker and DAR optimization.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/recent-advances-in-bispecific-antibody-drug-conjugates-for-breast-cancer-therapy/356264/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/recent-advances-in-bispecific-antibody-drug-conjugates-for-breast-cancer-therapy/356264.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are bispecific antibody-drug conjugates considered promising for breast cancer therapy?","Question",{"text":63,"@type":64},"BsADCs are designed to overcome limitations of conventional ADCs, particularly tumor heterogeneity and inefficient internalization. Their dual-targeting approach aims to enhance selectivity and cellular uptake.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do biparatopic HER2-targeting BsADCs improve drug delivery?",{"text":68,"@type":64},"They bind two non-overlapping HER2 epitopes to induce receptor clustering and robust internalization. Examples discussed include agents such as ZW49 and JSKN003.",{"name":70,"@type":61,"acceptedAnswer":71},"What strategies enable BsADCs to show efficacy in challenging subtypes like TNBC?",{"text":72,"@type":64},"The review describes approaches that target compensatory pathways, such as EGFR×HER3 (e.g., BL-B01D1) and TROP2×HER3 (e.g., JSKN016). These designs support activity even when single targets are limited.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356264,1790794256,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Cancer Chemotherapy and Pharmacology (2026) 96:15  \n[https://doi.org/10.1007/s00280-025-04863-9](https://doi.org/10.1007/s00280-025-04863-9)  \nREVIEW ARTICLE  \nRecent advances in bispecific antibody-drug conjugates for breast cancer therapy  \nXuan Ji1 · Yalong Yang1 · Cong Ma1 · Wenqin Huang1 · Senyang Guo1 · Lingzi Wang1 · Hongmei Zheng1 · XinhongWu1  \nReceived: 7 September 2025 / Accepted: 22 December 2025 © The Author(s) 2026  \nAbstract  \nPurpose Bispecific antibody-drug conjugates (BsADCs) represent a promising strategy to overcome limitations of conventional ADCs in breast cancer, such as tumor heterogeneity and inefficient internalization. This review summarizes recent advances and the therapeutic potential of BsADCs.  \nMethods We conducted a literature review, focusing on BsADC candidates selected for clinical relevance (e.g., ZW49, BL-B01D1), mechanistic innovation (e.g., biparatopic targeting, engaging fast-internalizing receptors), and potential in challenging subtypes like triple-negative breast cancer (TNBC) .  \nResults BsADCs enhance drug delivery through dual targeting. Biparatopic HER2-targeting agents (e.g., ZW49, JSKN003) induce receptor clustering and robust internalization. BsADCs co-engaging rapidly internalizing receptors (e.g., HER2×CD63) hijack efficient endocytic pathways, showing activity even in low HER2-expression models. Furthermore, BsADCs targeting compensatory pathways, such as EGFR×HER3 (BL-B01D1) and TROP2×HER3 (JSKN016), have demonstrated breakthrough efficacy in TNBC. Optimization of linker technology and drug-to-antibody ratio (DAR) has improved stability and the therapeutic window, enabling the progression of several BsADCs into Phase III trials.  \nConclusion BsADCs are a transformative therapeutic modality for breast cancer. Their ability to enhance tumor selectivity, overcome heterogeneity, and target resistant pathways positions them as key players in the future oncology landscape, with ongoing trials poised to define their clinical role.  \nKeywords Bispecific antibody-drug conjugate · Breast cancer · HER2 · TROP2 · Targeted therapy · Drug resistance  \nIntroduction  \nBreast cancer is one of the most common malignant tumors among women worldwide, and the incidence rate is increasing year by year [1, 2] . The treatment landscape for breast cancer has profoundly evolved into an era of precise molecular subtyping and individualized therapy [3] . Despite these advances, formidable challenges such as intrinsic and  \n􀀍 Hongmei Zheng [2022ZL0002@hust.edu.cn](2022ZL0002@hust.edu.cn)  \n􀀍 Xinhong Wu [2019zl0002@hust.edu.cn](2019zl0002@hust.edu.cn)  \n1 Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Clinical Research Center for Cancer, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, No.116 Zhuo Daoquan South Road, Wuhan 430079, Hubei, China  \nacquired drug resistance, profound tumor heterogeneity, and target escape remain the major bottlenecks to achieving durable clinical responses [4] .  \nAntibody-drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker [5] . ADC is a vector-based chemotherapy that allows the selective delivery of a potent cytotoxic agent within a tumor [6] . Traditionally, ADCs were produced through stochastic conjugation, leading to a heterogeneous mixture of molecules with varying DARs and conjugation sites. However, thereis a strong trend towards site-specific conjugation technologies (e.g., engineering cysteines, incorporating non-natural amino acids, or utilizing enzymatic conjugation) . These methods generate homogeneous ADCs with defined DARs, which often exhibit improved pharmacokinetics, enhanced stability, and a broader therapeutic window compared to their heterogeneous counterparts [7] .  \n1 3  \nCurrently, ADCs are an important class of ","cbCaidOpEfJEFStI","https://ap.wps.com/l/cbCaidOpEfJEFStI","pdf",1839428,"English","# Introduction\n## Breast cancer treatment challenges and ADC background\n# Mechanisms and design of BsADCs\n## Dual targeting, receptor clustering, and internalization\n## Fast-internalizing receptor engagement strategies\n## Targeting resistance-related compensatory pathways\n# Linker and DAR optimization\n## Stability and therapeutic window improvements\n# Conclusion\n## Clinical positioning and ongoing trials","[{\"question\":\"Why are bispecific antibody-drug conjugates considered promising for breast cancer therapy?\",\"answer\":\"BsADCs are designed to overcome limitations of conventional ADCs, particularly tumor heterogeneity and inefficient internalization. Their dual-targeting approach aims to enhance selectivity and cellular uptake.\"},{\"question\":\"How do biparatopic HER2-targeting BsADCs improve drug delivery?\",\"answer\":\"They bind two non-overlapping HER2 epitopes to induce receptor clustering and robust internalization. Examples discussed include agents such as ZW49 and JSKN003.\"},{\"question\":\"What strategies enable BsADCs to show efficacy in challenging subtypes like TNBC?\",\"answer\":\"The review describes approaches that target compensatory pathways, such as EGFR×HER3 (e.g., BL-B01D1) and TROP2×HER3 (e.g., JSKN016). These designs support activity even when single targets are limited.\"}]","Recent advances in bispecific antibody-drug conjugates for breast cancer therapy | PDF",1790124322,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15850263db2e8354aec6115156c07a3e.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac971f616d25a75df49af801fa3cf212.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3bcf9c435c928353d1d92dc7b84b6dd1.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b24e24e3322090a3d1fc95edb0a4d291.webp",980,1301]